サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1786464

ドラッグ・デリバリー・デバイスの世界市場

Drug and Gene Delivery Devices

出版日
ページ情報
英文 278 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
ドラッグ・デリバリー・デバイスの世界市場
出版日: 2025年08月08日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 278 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ドラッグ・デリバリー・デバイスの世界市場は2030年までに22億米ドルに達する

2024年に14億米ドルと推定されるドラッグ・デリバリー・デバイスの世界市場は、分析期間2024-2030年にCAGR 7.5％で成長し、2030年には22億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである経口は、CAGR 7.0％を記録し、分析期間終了時には5億1,030万米ドルに達すると予測されます。吸入セグメントの成長率は、分析期間中CAGR 8.9％と推定されます。

米国市場は3億8,610万米ドルと推定、中国はCAGR11.6％で成長予測

米国のドラッグ・デリバリー・デバイス市場は、2024年に3億8,610万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億5,900万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.8%と7.2%と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

世界のドラッグ・デリバリー・デバイス市場- 主要動向と促進要因のまとめ

ドラッグ・デリバリー・デバイスを形成する画期的イノベーションとは？

ドラッグ・デリバリー・デバイス市場は、バイオテクノロジー、ナノ医療、先端材料科学における最先端のイノベーションによって、急速な変貌を遂げています。これらのデバイスは、もはや治療薬の単なる導管ではなく、薬物や遺伝物質の特異性、安定性、バイオアベイラビリティを高める、ますます洗練されたプラットフォームとなりつつあります。CRISPR-Cas9やRNA干渉（RNAi）のような技術が急増しており、標的外影響を最小限に抑えつつ、影響を受ける細胞を正確に標的化できる送達システムが必要とされています。脂質ナノ粒子、ウイルスベクター、エレクトロポレーション技術などの新しい送達メカニズムが、これらの精密療法をサポートするために登場してきました。さらに、特に細胞内へのアクセスを必要とする遺伝子治療において、生物学的障壁を克服し、全身吸収を改善するために、ポリマーベースの送達ビヒクルやマイクロニードルアレイが活発に開発されています。このような開発により、以前は送達の制限のために実行不可能であった治療が可能になりつつあります。

個別化医療が新たなデリバリー・プラットフォームへの需要に拍車をかけているのはなぜか？

個別化医療と精密医療への移行は、治療デリバリー要件を再定義し、カスタマイズされたドラッグ・デリバリー・デバイスの開発を不可欠なものにしています。個人の遺伝的プロファイルに基づいた治療の調整には、様々な分子量、溶解度特性、組織標的に適応できるデリバリーシステムが必要です。ゲノム配列の解析がより速く、より身近になるにつれ、市場は、特に腫瘍学、希少疾患、慢性疾患において、患者に特化した治療に対する需要が高まっています。このため、迅速に構成できる柔軟性の高いモジュール式送達システムに対するニーズが高まっています。さらに、低分子と遺伝子ペイロードを組み合わせた併用療法の台頭により、デュアルまたはマルチモーダルな送達機能が必要とされています。規制当局もまた、個別化治療薬の複雑な性質に対応できるよう枠組みを進化させており、次世代送達デバイスの承認と市場参入を加速させています。

非侵襲的・標的送達法は市場進化においてどのような役割を果たすか？

患者の嗜好の変化やヘルスケア提供者の優先順位が、非侵襲的かつ部位特異的なデリバリー技術への大きな投資に拍車をかけています。経口、経鼻、肺、経皮投与は、患者のコンプライアンスと投与の容易さから、注射剤よりも人気が高まっています。特に、吸入可能な遺伝子治療分野は勢いを増しており、嚢胞性線維症や肺高血圧症などの呼吸器疾患に対して実用的な代替手段を提供しています。センサー、マイクロプロセッサー、接続機能を備えたスマート送達デバイスもこのシフトに寄与しており、治療投与と治療結果のリアルタイムモニタリングを可能にしています。これらのデバイスは、特に在宅ケア環境において、デジタルヘルスエコシステムに不可欠なものとなりつつあります。さらに、抗体薬物複合体（ADC）、アプタマー・システム、磁場誘導型ナノ粒子によって達成される部位特異的ターゲティングは、全身毒性を低減し治療効果を高め、より安全で効率的な治療への道を開いています。

ドラッグ・デリバリー・デバイス市場の成長はいくつかの要因に牽引されている...

ナノ・マイクロスケール工学の急速な技術進歩は、送達プラットフォームの設計と性能に革命をもたらし、これまでにない制御放出と標的送達を可能にしています。慢性疾患や遺伝性疾患の増加は、遺伝子治療や核酸ベースの薬剤の臨床試験の増加とともに、適合するデリバリー・システムに対する市場の需要を促進しています。最終用途の観点から見ると、製薬会社は生物学的製剤ポートフォリオを差別化し、新規製剤によって特許期間を延長するため、次世代送達システムに多額の投資を行っています。学術研究機関やCRO（医薬品開発業務受託機関）も、共同開発プログラムを通じてパイプラインの拡充に貢献しています。消費者側では、特に高齢化社会と小児医療において、低侵襲または自己投与可能な治療法への嗜好が高まっています。これと並行して、ヘルスケアプロバイダーは、患者のモニタリングや治療の最適化のためにデータエコシステムと統合したデリバリーソリューションを求めています。これらの動向が相まって、市場情勢は世界的に堅調でダイナミックな様相を呈しています。

セグメント

投与経路（経口、吸入、経皮、注射、眼、鼻、局所）;ベクター（ウイルス、非ウイルス）

調査対象企業の例

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Becton, Dickinson and Company（BD）
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Kite Pharma, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Oxford BioMedica plc
  • Pfizer Inc.
  • Sarepta Therapeutics, Inc.
  • Shanghai Sunway Biotech Co., Ltd.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP30606

Global Drug and Gene Delivery Devices Market to Reach US$2.2 Billion by 2030

The global market for Drug and Gene Delivery Devices estimated at US$1.4 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Oral, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$510.3 Million by the end of the analysis period. Growth in the Inhalation segment is estimated at 8.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$386.1 Million While China is Forecast to Grow at 11.6% CAGR

The Drug and Gene Delivery Devices market in the U.S. is estimated at US$386.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$459.0 Million by the year 2030 trailing a CAGR of 11.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Drug and Gene Delivery Devices Market - Key Trends & Drivers Summarized

How Are Breakthrough Innovations Reshaping Drug and Gene Delivery Devices?

The drug and gene delivery devices market has undergone rapid transformation, driven by cutting-edge innovations in biotechnology, nanomedicine, and advanced material sciences. These devices are no longer just conduits for therapeutic agents but are becoming increasingly sophisticated platforms that enhance specificity, stability, and bioavailability of drugs and genetic material. Techniques like CRISPR-Cas9 and RNA interference (RNAi) have surged in prominence, requiring delivery systems that can precisely target affected cells while minimizing off-target effects. Novel delivery mechanisms such as lipid nanoparticles, viral vectors, and electroporation technologies have emerged to support these precision therapies. Additionally, polymer-based delivery vehicles and microneedle arrays are being actively developed to overcome biological barriers and improve systemic absorption, especially for gene therapies requiring intracellular access. These developments are enabling therapies that were previously not viable due to delivery limitations.

Why Is Personalized Medicine Fueling the Demand for Novel Delivery Platforms?

The transition toward personalized and precision medicine has redefined therapeutic delivery requirements, making the development of customized drug and gene delivery devices essential. Tailoring treatments based on individual genetic profiles demands delivery systems that can adapt to varying molecular weights, solubility characteristics, and tissue targets. As genomic sequencing becomes faster and more accessible, the market is experiencing increased demand for patient-specific therapies, particularly in oncology, rare diseases, and chronic conditions. This has led to a growing need for flexible and modular delivery systems that can be rapidly configured. Furthermore, the rise of combination therapies-blending small molecules with genetic payloads-necessitates dual or multi-modal delivery capabilities. Regulatory agencies are also evolving their frameworks to accommodate the complex nature of personalized therapeutics, which is accelerating approvals and market entry of next-generation delivery devices.

What Role Do Non-Invasive and Targeted Delivery Methods Play in Market Evolution?

Shifting patient preferences and healthcare provider priorities have spurred significant investment in non-invasive and site-specific delivery technologies. Oral, nasal, pulmonary, and transdermal routes are gaining popularity over injectable formats due to better patient compliance and ease of administration. In particular, the inhalable gene therapy segment is gaining momentum, offering a practical alternative for respiratory diseases such as cystic fibrosis and pulmonary hypertension. Smart delivery devices equipped with sensors, microprocessors, and connectivity features are also contributing to this shift, enabling real-time monitoring of therapeutic administration and outcomes. These devices are becoming integral to digital health ecosystems, especially in home-care settings. Moreover, site-specific targeting-achieved through antibody-drug conjugates (ADCs), aptamer systems, and magnetic field-guided nanoparticles-is reducing systemic toxicity and enhancing therapeutic efficacy, paving the way for safer, more efficient treatments.

The Growth in the Drug and Gene Delivery Devices Market Is Driven by Several Factors…

Rapid technological advancements in nano- and micro-scale engineering have revolutionized the design and performance of delivery platforms, enabling controlled release and targeted delivery like never before. The rise in chronic and genetic diseases, alongside increasing clinical trials for gene therapies and nucleic acid-based drugs, is propelling market demand for compatible delivery systems. From an end-use perspective, pharmaceutical companies are investing heavily in next-gen delivery systems to differentiate their biologic portfolios and extend patent life through novel formulations. Academic research institutions and contract research organizations (CROs) are also contributing to pipeline expansion through collaborative development programs. On the consumer side, there is a growing preference for minimally invasive or self-administrable treatment modalities, especially in the aging population and pediatric groups. In parallel, healthcare providers are seeking delivery solutions that integrate with data ecosystems for patient monitoring and treatment optimization. Together, these trends are forging a robust and dynamic market landscape for drug and gene delivery devices globally.

SCOPE OF STUDY:

The report analyzes the Drug and Gene Delivery Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical); Vector (Viral, Non-viral)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Becton, Dickinson and Company (BD)
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Kite Pharma, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Oxford BioMedica plc
  • Pfizer Inc.
  • Sarepta Therapeutics, Inc.
  • Shanghai Sunway Biotech Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Drug and Gene Delivery Devices - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Chronic and Genetic Disorders Accelerates Demand for Advanced Drug and Gene Delivery Devices
    • Breakthroughs in mRNA Technology Strengthen the Business Case for Next-Generation Delivery Platforms
    • Growing Pipeline of Biologics and Cell & Gene Therapies Expands Addressable Market Opportunity for Novel Delivery Systems
    • Emergence of Personalized Medicine Spurs Innovation in Targeted and Localized Delivery Technologies
    • Favorable Regulatory Pathways and Fast-Track Approvals Propel Growth in Gene Therapy Delivery Solutions
    • Advancements in Nanocarriers and Lipid-Based Delivery Systems Drive Adoption in Precision Medicine
    • Increased Focus on Blood-Brain Barrier Penetration Throws the Spotlight on Intranasal and Intrathecal Delivery Methods
    • Rising Investment in Non-Viral Vectors Enhances Market Potential for Safer and Scalable Gene Delivery Approaches
    • Minimally Invasive Delivery Techniques Generate Demand for Needle-Free and Implantable Drug Delivery Devices
    • Shift Toward At-Home Treatment Models Sustains Growth of Wearable and Self-Administered Drug Delivery Systems
    • Strategic Collaborations Between Pharma and MedTech Firms Propel Innovation in Hybrid Drug-Device Products
    • Challenges in Payload Stability and Targeted Delivery Create Opportunities for Formulation-Device Integration
    • Growing Global Access to Advanced Therapies Drives Expansion of Drug and Gene Delivery Infrastructure in Emerging Markets
    • Evolving Regulatory Standards for Combination Products Create Both Hurdles and Opportunities in Product Commercialization
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Drug and Gene Delivery Devices Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Drug and Gene Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Drug and Gene Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Inhalation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Transdermal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ocular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ocular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Ocular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Nasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Nasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Nasal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Non-viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Non-viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Non-viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • JAPAN
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • CHINA
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • EUROPE
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Drug and Gene Delivery Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Drug and Gene Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • FRANCE
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • GERMANY
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Drug and Gene Delivery Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Drug and Gene Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • INDIA
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Drug and Gene Delivery Devices by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Drug and Gene Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Drug and Gene Delivery Devices by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Drug and Gene Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • AFRICA
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030

IV. COMPETITION